Neovasc Stock Forecast, Price & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVCN shares have decreased by 3.2% and is now trading at $2.14.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) released its earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.22. The medical equipment provider had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.30 million.
View Neovasc's earnings history.

Neovasc's stock reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $295K - 295K.

4 brokerages have issued 1 year price objectives for Neovasc's stock. Their forecasts range from $3.00 to $15.00. On average, they expect Neovasc's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 238.8% from the stock's current price.
View analysts' price targets for Neovasc.

Neovasc saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 82,800 shares, an increase of 13.4% from the August 31st total of 73,000 shares. Based on an average trading volume of 341,800 shares, the short-interest ratio is presently 0.2 days. Approximately 0.4% of the company's shares are short sold.
View Neovasc's Short Interest.

Some companies that are related to Neovasc include Liquidia Technologies (LQDA), T2 Biosystems (TTOO), Apyx Medical (APYX), Lyra Therapeutics (LYRA), Soliton (SOLY), DarioHealth (DRIO), Pro-Dex (PDEX), PAVmed (PAVM), Restoration Robotics (HAIR), Venus Concept (VERO), BeyondAirInc . (XAIR), ClearPoint Neuro (CLPT), Neuronetics (STIM), Spectral Medical (EDTXF) and SANUWAVE Health (SNWV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), 22nd Century Group (XXII), Heat Biologics (HTBX), Protalix Biotherapeutics (PLX), TOP SHIPS (TOPS) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (5.68%), Sabby Management LLC (2.93%), Two Sigma Advisers LP (0.29%), Wedbush Securities Inc. (0.40%) and Bank of America Corp DE (0.18%).

NVCN stock was bought by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Sabby Management LLC, Wedbush Securities Inc., Two Sigma Advisers LP, and Bank of America Corp DE.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.14.

Neovasc has a market capitalization of $48.46 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]